Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.

The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

The advanced wound care market is attracting an increasing number of competitors and investors seeking a stake in this high-need, high-growth space. But although the number of innovative wound care products is on the rise, this is also a highly diverse market, with some striking differences among various regions of the world in terms of product adoption and standard wound care practices.